All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

Rat Advanced glycosylation end product-specific receptor(AGER) ELISA kit

Promotion
Protocol MSDS
Code CSB-EL001441RA
Size 96T,5×96T,10×96T
Price Request a Quote
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase within six months until depleted. More details >>
Interested in a trial size? Please leave a message below.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
advanced glycosylation end product-specific receptor
Alternative Names
Ager ELISA Kit; Rage ELISA Kit; Advanced glycosylation end product-specific receptor ELISA Kit; Receptor for advanced glycosylation end products ELISA Kit
Abbreviation
AGER
Uniprot No.
Q63495
Species
Rattus norvegicus (Rat)
Sample Types
serum, plasma,tissue homogenates
Detection Range
31.25 pg/mL-2000 pg/mL
Sensitivity
7.81 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Immunology
Assay Principle
quantitative
Measurement
Sandwich
Precision

Intra-assay Precision (Precision within an assay): CV%<8%

Three samples of known concentration were tested twenty times on one plate to assess.

Inter-assay Precision (Precision between assays): CV%<10%

Three samples of known concentration were tested in twenty assays to assess.

　

Intra-Assay Precision

Inter-Assay Precision

Sample

1

2

3

1

2

3

n

20

20

20

20

20

20

Mean(pg/ml)

224.423

224.423

225.339

224.377

225.431

224.881

SD

0.034

0.030

0.031

0.040

0.037

0.039

CV(%)

4.433

3.911

4.031

5.216

4.810

5.078

Linearity

To assess the linearity of the assay, samples were spiked with high concentrations of rat AGER in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.

　

Sample

Serum(n=4)

1:1

Average %

92

Range %

90-94

1:2

Average %

96

Range %

90-102

1:4

Average %

102

Range %

99-105

1:8

Average %

87

Range %

80-94

Recovery

The recovery of rat AGER spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.

Sample Type

Average % Recovery

Range

Serum (n=5)

90

87-95

EDTA plasma (n=4)

101

97-106

Typical Data

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.

pg/ml

OD1

OD2

Average

Corrected

2000

2.703

2.878

2.791

2.615

1000

1.903

1.856

1.880

1.704

500

1.245

1.154

1.200

1.024

250

0.731

0.747

0.739

0.563

125

0.556

0.533

0.545

0.369

62.5

0.402

0.392

0.397

0.221

31.25

0.272

0.275

0.274

0.098

0

0.173

0.179

0.176

　

ELISA Data Analysis
ELISA Standard Curve & Curve Expert software
Troubleshooting
and FAQs
ELISA kit FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Shelf Life
6 months
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx.
Description

This Rat Advanced glycosylation end product-specific receptor (AGER) ELISA kit is a powerful tool for researchers in the field of immunology. It allows for the accurate and reliable quantification of Rat AGER levels in serum, plasma, and tissue homogenates.

It is designed for quick and easy detection of AGER in Rat samples, and has a wide detection range of 31.25 pg/mL to 2000 pg/mL, with a sensitivity of 7.81 pg/mL. The assay time is only 1-5 hours, and the sample volume required is just 50-100ul, making it an ideal choice for high-throughput screening.

The kit uses a sandwich assay principle for quantitative measurement of Rat AGER levels, and it can be read using a standard 450 nm wavelength detector. The kit can be used in a research setting and is suitable for a variety of applications within the field of immunology. By accurately measuring AGER levels, researchers can gain valuable insights into the role of this protein in immune system function and disease.

Related Products

Ager Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling.
Subcellular Location
Membrane; Single-pass type I membrane protein.
Tissue Specificity
Endothelial cells and cardiomyocytes.
Database Links
Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

Related Articles
Information You Must Know about KCNN4 DLL3: A New Molecular Target in Cancer TPBG/5T4: the Oncofetal Protein, an Appealing Target for ADC or Vaccine Therapeutics in Tumors! Latest Changes in Journal Impact Factor Mucin-17/MUC17: An Unexpected Target for Tumor Immune Therapy, Notably Gastric Cancer! Myosin Regulatory Light Chains (MYL12A and MYL12B): the New Functional Ligands for CD69, Potential Targets for Cardiac Disease or Tumors Research? The Overview of Growth Factor Tumor Necrosis Factor (TNF) Targeting LRRC15: From tumor microenvironment regulation to fibrotic/infectious disease therapy In Vivo vs. In Vitro: Choosing the Right Experimental Model for Your Research CD79A and CD79B: Key Targets in B Cell Signaling Pathways and Therapeutic Potential TNFRSF13C (BAFF-R): A Key Target for Immune Regulation and Disease Treatment Interleukin-2 (IL2): The "Double-Edged Sword" of the Immune System Immune Battlefield's "Scout": Decoding the NCR3 Target B7-H6: A Key Ligand of NK Cell Immune Checkpoints Reshaping the Landscape of Tumor Immunotherapy Targeting the "Hidden Target" ROR1: A Breakthrough for Broad-Spectrum Cancer Therapy? ELISA Data Analysis How to Do The Pre-experiment before Your ELISA Experiment Four Types of ELISA 11 tips for choosing your right ELISA kit Do you Often Trouble in These Problems of ELISA? Problems and Solutions in ELISA Experiments
Related pathways
AGE-RAGE signaling pathway in diabetic complications
CUSABIO guaranteed quality
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*